Gelteq Limited Stock Price, News & Analysis

Gelteq (NASDAQ: GELS) announces that its brand Sportsgel has become the official sponsor of the Professional Pickleball Tour and League of Australia and New Zealand. The three-year sponsorship agreement grants Gelteq exclusivity for consumable performance, health, recovery, and sports-related gels with both PPAA and MLPA.

The partnership includes on-court branding at all PPAA and MLPA events, team apparel branding, and presence across social and digital platforms. The leagues feature prominent owners including former World No.1 golfer Adam Scott, NBA Star Patty Mills, five-time Olympian Nat Cook, and cricketer Steve Smith.

The collaboration aims to develop tailored, league-branded products specifically designed for pickleball players, leveraging Gelteq's gel-based delivery platform and the expertise of their new Head of Sports Performance, Matthew Jones.

Gelteq (NASDAQ: GELS) has announced the launch of its SportsGel brand and secured a distribution agreement with WPIC Marketing and Technologies for the Asia-Pacific region. The company's first market entry will be in China during H1 2025, targeting the country's sports nutrition market, valued at $6.5 billion in 2022 with a projected annual growth rate of 9.1% until 2027.

SportsGel will initially launch sports-specific gels for running and cycling, along with a functional hydration product. The brand aims to provide improved sports performance solutions without compromising taste, mouthfeel, and convenience. Matthew Jones, Gelteq's Head of Sports Performance, will oversee all SportsGel formulations, which will be available for licensing to companies interested in Gelteq's proprietary delivery system.

Gelteq (NASDAQ: GELS) has appointed Matthew Jones as Head of Sports Performance to oversee the growth, outreach, and customer strategy of its sports vertical. Jones, an internationally-experienced sports dietitian, currently serves as Head of Nutrition with the UAE Football Association and consults for the Boston Celtics.

Jones brings over 12 years of elite sports experience, including work in international football, English Premier League, Women's Super League, and NCAA Division I sports. He holds a Master's Degree in Nutrition Science from University of Chester and is registered with the British Dietetic Association, Sport Nutrition Register.

The appointment aligns with Gelteq's strategy to expand its ingestible gel technology in sports nutrition, leveraging its unique formulation for improved nutrient delivery compared to traditional methods.

Gelteq (NASDAQ: GELS) has appointed Dr. Paul Wynne as its new Chief Scientific Officer (CSO). Dr. Wynne brings over 35 years of experience in analytical chemistry, advanced materials, drug metabolism, pharmaceutical formulation, and drug delivery. Prior to joining Gelteq, he served as Manager of the Medicines Manufacturing Innovation Centre at Monash University for eight years.

In his new role, Dr. Wynne will oversee product and formulation strategies, lead the scientific team's growth, manage the company's intellectual property portfolio, and coordinate with manufacturing partners. His expertise includes authoring over 80 peer-reviewed papers and 120 industry presentations. He holds multiple advanced degrees from RMIT University, including a PhD in Chemistry and Toxicology.

Gelteq (NASDAQ: GELS) has received FDA approval for its suitability petition for a new animal drug development, marking its entry into the animal pharmaceuticals market. The approval enables a fast-track pathway through an abbreviated new animal drug application (ANADA) for converting an existing FDA-approved generic animal drug from pill form to an oral gel form using Gelteq's ingestible gel platform.

The FDA's approval under section 512(n)(3)(C) of the FD&C Act eliminates the need for additional safety and effectiveness studies, potentially reducing the timeframe for final drug approval. However, the company notes that this suitability petition approval does not guarantee final ANADA approval for the proposed generic new animal drug.

Gelteq (NASDAQ: GELS), a company specializing in gel-based delivery solutions for various products including prescription drugs and pet care, has announced its participation in the Benchmark Company 13th Annual Discovery Investor Conference. The event will take place on December 11, 2024, at the New York Athletic Club in New York City.

Co-Founders Nathan Givoni (CEO) and Simon Szewach (Executive Chairman) will be available for one-on-one meetings with analysts and investors throughout the conference day. Interested attendees can arrange meetings through their Benchmark Company representative.

Gelteq (NASDAQ: GELS) announces that its largest U.S. customer, Healthy Extracts, has increased its initial purchase order of collagen and Mynus sugar blocker gels by 50% due to high market demand. The production is underway with shipment expected in January 2025. This expansion follows Gelteq's strategic U.S. market entry, including the recent appointment of Adam Bendell as U.S. President. The partnership aims to provide improved delivery solutions for nutraceutical products, focusing on easier digestion and better absorption.

Gelteq (NASDAQ: GELS) announces the production of 400,000 units of its gel solution in November 2024. The production run includes nutraceutical products for sports, anti-aging, and weight loss, fulfilling orders for clients in the U.S. and Australia. Delivery is expected in January 2025, with sales extending to the UAE and Asia. The company states this production milestone follows their recent IPO and demonstrates their ability to execute large-scale sales while maintaining research and development activities. Gelteq also highlights their strengthened partnership with Monash Innovation Labs to ensure quality and scalability.

Gelteq (NASDAQ: GELS) has expanded its U.S. operations by appointing Adam Bendell as President of U.S. Operations. Bendell, who brings nearly a decade of experience in corporate strategy and retail operations, has previously worked with global brands including Deloitte Consulting, Calvin Klein, Tommy Hilfiger, and Cole Haan. The appointment aligns with Gelteq's growth strategy to scale operations in the U.S. market. The company specializes in developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, and pet care products.